Reviewing CymaBay Therapeutics Inc. (CBAY)’s and Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s results

CymaBay Therapeutics Inc. (NASDAQ:CBAY) and Iovance Biotherapeutics Inc. (NASDAQ:IOVA) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CymaBay Therapeutics Inc. 5.21M 108.67 58.14M -1.04 0.00
Iovance Biotherapeutics Inc. N/A 0.00 116.86M -1.37 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of CymaBay Therapeutics Inc. and Iovance Biotherapeutics Inc.


Table 2 provides CymaBay Therapeutics Inc. and Iovance Biotherapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
CymaBay Therapeutics Inc. -1,115.93% -34% -30.7%
Iovance Biotherapeutics Inc. 0.00% -48.6% -45.9%

Risk & Volatility

A 1.76 beta indicates that CymaBay Therapeutics Inc. is 76.00% more volatile compared to S&P 500. Iovance Biotherapeutics Inc.’s 165.00% more volatile than S&P 500 volatility due to the stock’s 2.65 beta.


The current Quick Ratio of CymaBay Therapeutics Inc. is 14.8 while its Current Ratio is 14.8. Meanwhile, Iovance Biotherapeutics Inc. has a Current Ratio of 15.9 while its Quick Ratio is 15.9. Iovance Biotherapeutics Inc. is better positioned to pay off its short-term and long-term debts than CymaBay Therapeutics Inc.

Analyst Recommendations

Ratings and Recommendations for CymaBay Therapeutics Inc. and Iovance Biotherapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CymaBay Therapeutics Inc. 0 1 0 2.00
Iovance Biotherapeutics Inc. 0 0 0 0.00

CymaBay Therapeutics Inc.’s downside potential is -5.46% at a $9 consensus price target.

Insider & Institutional Ownership

CymaBay Therapeutics Inc. and Iovance Biotherapeutics Inc. has shares held by institutional investors as follows: 93.7% and 78.7%. Insiders held 0.3% of CymaBay Therapeutics Inc. shares. Competitively, insiders own roughly 1.12% of Iovance Biotherapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CymaBay Therapeutics Inc. -2.02% -25.02% -32.69% -29.32% 5.8% -4.89%
Iovance Biotherapeutics Inc. 3.93% 9.84% -22.39% -19.28% 17.54% 25.63%

For the past year CymaBay Therapeutics Inc. had bearish trend while Iovance Biotherapeutics Inc. had bullish trend.


On 7 of the 10 factors CymaBay Therapeutics Inc. beats Iovance Biotherapeutics Inc.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes. CymaBay Therapeutics Inc. has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products containing halofenate, its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics Inc. was incorporated in 1988 and is headquartered in Newark, California.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patientÂ’s TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.